Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kyoung Min Cho | - |
dc.contributor.author | Bhumsuk Keam | - |
dc.contributor.author | Hyerim Ha | - |
dc.contributor.author | Miso Kim | - |
dc.contributor.author | Jae-Woo Jung | - |
dc.contributor.author | Woo-Jung Song | - |
dc.contributor.author | Tae Min Kim | - |
dc.contributor.author | Yoon Kyung Jeon | - |
dc.contributor.author | Hye-Ryun Kang | - |
dc.contributor.author | Dong-Wan Kim | - |
dc.contributor.author | Chul Woo Kim | - |
dc.contributor.author | Dae Seog Heo | - |
dc.date.available | 2019-08-19T05:57:21Z | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/34114 | - |
dc.description.abstract | Background/Aims: This study was to evaluate the clinical significance of infusion- related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods: The medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor’s progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria. Results: IRR was not associated with overall survival (OS) or progression-free survival (PFS) of DLBCL patients as compared to those who did not have IRR (OS: median 78.0 months vs. 69.0 months, p = 0.700; PFS: median 65.4 months vs. 64.0 months, p = 0.901). IRR grade did not affect OS or PFS. B symptoms was independently associated with IRR (hazard ratio [HR], 1.850; 95% confidence interval [CI], 1.041 to 3.290; p = 0.036). Further, bone marrow involvement was independently associated with re-IRR (HR, 4.904; 95% CI, 0.767 to 3.118; p = 0.029). Conclusions: Our study shows that IRR of rituximab is not associated with OS or PFS of DLBCL patients who received R-CHOP. Furthermore, our study suggests a need for more careful observation for IRR in patients with B symptoms or bone marrow involvement. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한내과학회 | - |
dc.title | Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP | - |
dc.type | Article | - |
dc.identifier.doi | 10.3904/kjim.2017.036 | - |
dc.identifier.bibliographicCitation | The Korean Journal of Internal Medicine, v.34, no.4, pp 885 - 893 | - |
dc.identifier.kciid | ART002476097 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000475850300019 | - |
dc.identifier.scopusid | 2-s2.0-85069268404 | - |
dc.citation.endPage | 893 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 885 | - |
dc.citation.title | The Korean Journal of Internal Medicine | - |
dc.citation.volume | 34 | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Infusion-related reaction | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.subject.keywordAuthor | Lymphoma | - |
dc.subject.keywordAuthor | large B-cell | - |
dc.subject.keywordAuthor | diffuse | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Characteristics | - |
dc.subject.keywordPlus | ANTI-CD20 MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | CHEMOTHERAPY PLUS RITUXIMAB | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | CYTOKINE-RELEASE SYNDROME | - |
dc.subject.keywordPlus | BONE-MARROW INVOLVEMENT | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.